共 12 条
[1]
Neuroprotective therapy in Parkinson disease. Chen S,Le W. American Journal of Therapeutics . 2006
[2]
TOPA quinone,a kainate-like agonist and excitotoxin is generated by a catecholaminergic cell line. Newcomer TA,Rosenberg PA,Aizenman E. The Journal of Neuroscience . 1995
[3]
Free3-nitrotyrosine causes striatal neurodegeneration in vivo. Mihm MJ,Schanbacher BL,Wallace BL,et al. The Journal of Neuroscience . 2001
[4]
Duration of amantadine benefit on dyskinesia of severe Parkinson‘s disease. Thomas A,Iacono D,Luciano AL,et al. Journal of Neurology Neurosurgery and Psychiatry . 2004
[5]
Neuroprotection in Parkinson disease:mysteries,myths,and misconceptions. Schapira AH,Olanow CW. The Journal of The American Medical Association . 2004
[6]
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson‘s disease. The Parkinson study group. The New England Journal of Medicine . 1993
[7]
Treatment of Parkinson‘s disease:what‘s on the horizon. Wu SS,Frucht SJ. CNS Drugs . 2005
[8]
A double-blind,placebo-controlled and longitudinal study of riluzole in early Parkinson‘s disease. Jankovic J,Hunter C. Parkinsonism and Related Disorders . 2002
[9]
Effects of coenzyme Q10in early Parkinson disease:evidence of slowing of the functionaldecline. Shults CW,Oakes D,Kieburtz K,et al. Archives of Neurology . 2002
[10]
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. The Parkinson study group. The Journal of The American Medical Association . 2002